Suppr超能文献

内皮细胞miR-22的抑制介导非小细胞肺癌细胞诱导的血管生成。

Suppression of endothelial miR-22 mediates non-small cell lung cancer cell-induced angiogenesis.

作者信息

Gu Yuan, Pais Gianni, Becker Vivien, Körbel Christina, Ampofo Emmanuel, Ebert Elke, Hohneck Johannes, Ludwig Nicole, Meese Eckart, Bohle Rainer M, Zhao Yingjun, Menger Michael D, Laschke Matthias W

机构信息

Institute for Clinical and Experimental Surgery, Saarland University, 66421 Homburg/Saar, Germany.

Institute of Pathology, Saarland University, 66421 Homburg/Saar, Germany.

出版信息

Mol Ther Nucleic Acids. 2021 Oct 8;26:849-864. doi: 10.1016/j.omtn.2021.10.003. eCollection 2021 Dec 3.

Abstract

MicroRNAs (miRNAs) expressed in endothelial cells (ECs) are powerful regulators of angiogenesis, which is essential for tumor growth and metastasis. Here, we demonstrated that miR-22 is preferentially and highly expressed in ECs, while its endothelial level is significantly downregulated in human non-small cell lung cancer (NSCLC) tissues when compared to matched nontumor lung tissues. This reduction of endothelial miR-22 is possibly induced by NSCLC cell-secreted interleukin-1β and subsequently activated transcription factor nuclear factor-κB. Endothelial miR-22 functions as a potent angiogenesis inhibitor that inhibits all of the key angiogenic activities of ECs and consequently NSCLC growth through directly targeting sirtuin 1 and fibroblast growth factor receptor 1 in ECs, leading to inactivation of AKT/mammalian target of rapamycin signaling. These findings provide insight into the molecular mechanisms of NSCLC angiogenesis and indicate that endothelial miR-22 represents a potential target for the future antiangiogenic treatment of NSCLC.

摘要

在内皮细胞(ECs)中表达的微小RNA(miRNAs)是血管生成的有力调节因子,而血管生成对于肿瘤生长和转移至关重要。在此,我们证明miR-22在内皮细胞中优先且高表达,而与匹配的非肿瘤肺组织相比,其在内皮中的水平在人类非小细胞肺癌(NSCLC)组织中显著下调。内皮miR-22的这种减少可能是由NSCLC细胞分泌的白细胞介素-1β诱导的,随后激活转录因子核因子-κB。内皮miR-22作为一种有效的血管生成抑制剂,通过直接靶向内皮细胞中的沉默调节蛋白1和成纤维细胞生长因子受体1,抑制内皮细胞的所有关键血管生成活性,从而抑制NSCLC生长,导致AKT/雷帕霉素哺乳动物靶标信号失活。这些发现为NSCLC血管生成的分子机制提供了见解,并表明内皮miR-22代表了未来NSCLC抗血管生成治疗的潜在靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f26/8536510/7181fd4cfdbc/fx1.jpg

相似文献

9

引用本文的文献

本文引用的文献

1
Challenges identifying efficacious miRNA therapeutics for cancer.识别有效的癌症miRNA治疗方法面临的挑战。
Expert Opin Drug Discov. 2020 Sep;15(9):987-992. doi: 10.1080/17460441.2020.1765770. Epub 2020 May 18.
4
Cancer statistics, 2020.癌症统计数据,2020 年。
CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
6
Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation.微小RNA生物合成、作用机制及循环概述
Front Endocrinol (Lausanne). 2018 Aug 3;9:402. doi: 10.3389/fendo.2018.00402. eCollection 2018.
10
The Role of Angiogenesis in Cancer Treatment.血管生成在癌症治疗中的作用。
Biomedicines. 2017 Jun 21;5(2):34. doi: 10.3390/biomedicines5020034.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验